Kromek Group PLC Notice of AGM and Publication of Annual Report (1760L)
01 Septembre 2023 - 6:00PM
UK Regulatory
TIDMKMK
RNS Number : 1760L
Kromek Group PLC
01 September 2023
1 September 2023
Kromek Group plc
("Kromek" or the "Group")
Notice of AGM and Publication of Annual Report
Kromek (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and
CBRN detection segments, gives notice that its Annual General
Meeting ("AGM") will be held at 9:30am on Thursday 28 September
2023 in the Kromek 'Biosecurity' Boardroom at Explorer 1 Building,
North East Technology Park (NETPark), Thomas Wright Way,
Sedgefield, County Durham, TS21 3FF.
The notice of AGM and form of proxy, along with the Group's
annual report and accounts for the year ended 30 April 2023, have
today been posted to those shareholders who have requested paper
communications. These documents are also available on the Investor
Relations section of the Group's website at
https://www.kromek.com/investor-relations/ and can be accessed by
clicking on the "AGM 2023" page.
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO +44 (0)1740 626 060
finnCap Ltd (Nominated Adviser and Joint
Broker)
Geoff Nash/Seamus Fricker/George Dollemore
- Corporate Finance
Tim Redfern/Charlotte Sutcliffe - ECM +44 (0)20 7220 0500
Cenkos Securities plc (Joint Broker)
Giles Balleny - Corporate Finance
Michael Johnson/Tamar Cranford-Smith - Sales +44 (0)20 7397 8900
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments. Headquartered in County Durham, UK, Kromek
has manufacturing operations in the UK and US, delivering on the
vision of enhancing the quality of life through innovative
detection technology solutions.
The advanced imaging segment comprises the medical (including CT
and SPECT), security and industrial markets. Kromek provides its
OEM customers with detector components, based on its core cadmium
zinc telluride (CZT) platform, to enable better detection of
diseases such as cancer and Alzheimer's, contamination in
industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation
detection solutions to the global homeland defence and security
market. Kromek's compact, handheld, high-performance radiation
detectors, based on advanced scintillation and solid-state readout
technology, are primarily used to protect critical infrastructure,
events, personnel and urban environments from the threat of 'dirty
bombs'.
The Group is also developing bio-security solutions in the CBRN
detection segment. These consist of fully automated and autonomous
systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange,
under the trading symbol 'KMK'.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOANKDBQQBKDBCK
(END) Dow Jones Newswires
September 01, 2023 12:00 ET (16:00 GMT)
Kromek (LSE:KMK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Kromek (LSE:KMK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024